I've only quickly glossed over the agreement so far, looking for the bad news. Haven't found anything unexpected yet, other than it does appear that Bintai is paying for the U.S. clinical trials.
"Bintai will provide 100% funding for U.S. clinical development, manufacturing and commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in international markets"
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links